Lantheus Offers Low-Enriched Uranium Tc-99m Generator

Supports long-term strategy to eliminate use of highly enriched uranium (HEU)-produced molybdenum and technetium


January 16, 2013
Lantheus LEU TechneLite generator Mo-99 Nuclear Imaging Radiopharmeceuticals

Lantheus’ LEU TechneLite generator is the first technetium-99m (Tc-99m) generator in the United States that contains molybdenum-99 (Mo-99) produced from at least 95 percent LEU. With greater access to LEU Mo-99 through its supply chain diversification strategy, Lantheus can now move closer to its goal of eventually eliminating Highly Enriched Uranium (HEU)-sourced Mo-99 from its supply chain. Lantheus’ first LEU TechneLite generator was shipped on Jan. 7, 2013.

The TechneLite generator is used in many critical diagnostic imaging procedures, including scans of the heart, brain, bone, kidneys and some types of tumors. The introduction of our LEU TechneLite generator expands Lantheus' nuclear medicine product portfolio and meets CMS’ new reimbursement requirements for Medicare Hospital Outpatients in 2013, while supporting the government’s non-proliferation goal of moving away from the use of HEU in the production of medical isotopes.

In 2012, Lantheus announced expanded access to LEU-sourced Mo-99 with an extended agreement with NTP Radioisotopes in South Africa. Under the five-year agreement, Lantheus will receive an increasing supply of Mo-99 produced from LEU targets from NTP Radioisotopes (NTP) and Australian Nuclear Science and Technology Organisation (ANSTO). Additionally, Lantheus announced continued supply of Mo-99 from Nordion, which will be used in the production of the company’s non-LEU TechneLite generators.

For more information: